Last reviewed · How we verify

TJ Biopharma Co., Ltd. — Portfolio Competitive Intelligence Brief

TJ Biopharma Co., Ltd. pipeline: 0 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
TJ101 TJ101 phase 3
TJ202, Lenalidomide and Dexamethasone TJ202, Lenalidomide and Dexamethasone phase 3 Immunomodulator Cereblon Oncology
NordiFlex NordiFlex phase 3 PD-1 inhibitor PD-1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Materia Medica Holding · 2 shared drug classes
  2. ASLAN Pharmaceuticals · 1 shared drug class
  3. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  4. Actavis Mid-Atlantic LLC · 1 shared drug class
  5. Active Biotech AB · 1 shared drug class
  6. Addpharma Inc. · 1 shared drug class
  7. ATGC Co., Ltd. · 1 shared drug class
  8. ALK-Abelló A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for TJ Biopharma Co., Ltd.:

Cite this brief

Drug Landscape (2026). TJ Biopharma Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tj-biopharma-co-ltd. Accessed 2026-05-16.

Related